NEW YORK, August 6, 2014 /PRNewswire/ --
Today, Analysts Review released its research reports regarding Johnson Controls Inc. (NYSE: JCI), Intuitive Surgical, Inc. (NASDAQ: ISRG), GlaxoSmithKline plc (NYSE: GSK), Community Health Systems, Inc. (NYSE: CYH) and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5495-100free.
--
Johnson Controls Inc. Research Reports
On July 23, 2014, Johnson Controls Inc. (Johnson Controls) reported the signing of an agreement with Shanghai Yanfeng Industry and Commerce Co., Ltd. and Anhui Yansheng Automotive Trim Co., Ltd. to form a new fabrics joint venture in Huainan City, Anhui Province, China. The Company informed that the new joint venture, named Anhui New Nangang Johnson Controls Automotive Trim Co., Ltd., will offer Chinese automakers a variety of services including fabric design, engineering and manufacturing, and is expected to commence operation in October 2014. Commenting on the venture, Eric Sorret, Group Vice President and General Manager China, Johnson Controls Automotive Experience, said, "As the third fabrics facility in China, this new joint venture will leverage Johnson Controls' global capabilities, allowing us to support customers in differentiating their vehicle programs." The full research reports on Johnson Controls are available to download free of charge at:
http://www.analystsreview.com/Aug-06-2014/JCI/report.pdf
--
Intuitive Surgical, Inc.Research Reports
On July 24, 2014, Intuitive Surgical, Inc. (Intuitive Surgical) announced the launch of the first annual Intuitive Surgical Robotics Fellowship Course through the American Association for Thoracic Surgery's (AATS) Graham Foundation. The Company informed that the course will offer an introductory training course in robotics to eight North American general thoracic surgery fellows and their attending surgeons. "We welcome the opportunity to support surgeons early in their professional development as they experience advanced technologies that enable the delivery of more minimally invasive thoracic surgery," said Myriam Curet, Senior Vice President, Chief Medical Officer at Intuitive Surgical. Intuitive Surgical stated that it supported this course by providing funding, hosting, logistical support, da Vinci® System training and curriculum consultation to the AATS Graham Foundation. The full research reports on Intuitive Surgical are available to download free of charge at:
http://www.analystsreview.com/Aug-06-2014/ISRG/report.pdf
--
GlaxoSmithKline plc Research Reports
On July 31, 2014, GlaxoSmithKline plc (GSK) and its Ofatumumab development partner Genmab announced that an Independent Data Monitoring Committee interim analysis of a phase III study, PROLONG, demonstrated that treatment with ofatumumab (Arzerra') met the primary endpoint of improving progression free survival. The Company informed that the study evaluated ofatumumab maintenance therapy versus no further treatment (observation) in patients with relapsed chronic lymphocytic leukaemia who responded to treatment at relapse. "This interim result from the PROLONG study demonstrated that maintenance therapy with ofatumumab lowered the risk of disease progression in patients who responded to treatment at relapse. We look forward to sharing the results of the interim analysis with regulatory agencies to evaluate the potential for future regulatory filings," said Dr. Rafael Amado, Head of Oncology R&D, GSK. The full research reports on GlaxoSmithKline are available to download free of charge at:
http://www.analystsreview.com/Aug-06-2014/GSK/report.pdf
--
Community Health Systems, Inc. Research Reports
On July 31, 2014, Community Health Systems, Inc. (Community Health) announced its Q2 2014 financial results, which include Health Management Associates, Inc.'s (HMA) operating results from January 27, 2014, the date the Company completed its acquisition of HMA. Community Health's net operating revenue in Q2 2014 increased 49.8% YoY to $4.8 billion. Net income attributable to Community Health stockholders increased to $42.0 million, or $0.37 per diluted share in Q2 2014 from $30.0 million, or $0.32 per diluted share in Q2 2013. For full-year 2014, the Company projects net operating revenues (less provision for bad debts) of $19-19.8 billion. The full research reports on Community Health are availableto download free of charge at:
http://www.analystsreview.com/Aug-06-2014/CYH/report.pdf
--
Vertex Pharmaceuticals Incorporated Research Reports
On July 31, 2014, Vertex Pharmaceuticals Incorporated (Vertex) announced that KALYDECO' (ivacaftor) has been approved by European Commission for people with cystic fibrosis (CF) ages 6 and older who have one of eight non-G551D gating mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The Company informed that this approval has come after the positive opinion was received from the Committee for Medicinal Products for Human Use (CHMP) in June 2014. KALYDECO was first approved in Europe in July 2012 for people with CF ages 6 and older who have the G551D mutation. The latest approval includes eight additional gating mutations: G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P and G1349D. "Today's approval in people with additional gating mutations marks another step toward our goal of helping more people with this disease," said Simon Bedson, Senior Vice President and International General Manager at Vertex. The full research reports on Vertex are available to download free of charge at:
http://www.analystsreview.com/Aug-06-2014/VRTX/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
